Globus Medical, Inc. (NYSE:GMED) Stock Has Average Target Price of $96.08 According to Analysts

Globus Medical logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is moderately positive: 16 brokerages average a “Moderate Buy” rating, with a consensus 12-month price target of $96.08; several firms recently lowered their targets.
  • Quarterly results were mixed: Globus Medical reported EPS of $1.23, above the $1.20 consensus, but revenue of $763.7 million missed expectations and fell 0.7% year over year.
  • Company directors sold shares, and insiders sold 76,666 shares worth about $5.8 million over the last quarter.
  • Five stocks to consider instead of Globus Medical.

Globus Medical, Inc. (NYSE:GMED - Get Free Report) has earned an average rating of "Moderate Buy" from the sixteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $96.08.

A number of brokerages recently commented on GMED. Zacks Research lowered shares of Globus Medical from a "strong-buy" rating to a "hold" rating in a research note on Monday, November 9th. Canaccord Genuity Group lowered their price target on shares of Globus Medical from $115.00 to $105.00 and set a "buy" rating on the stock in a report on Friday, November 6th. Truist Financial cut their price objective on shares of Globus Medical from $100.00 to $90.00 and set a "buy" rating for the company in a research report on Monday, November 9th. BMO Capital Markets cut Globus Medical from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $94.00 to $78.00 in a report on Friday, November 6th. Finally, Needham & Company LLC reduced their price objective on Globus Medical from $117.00 to $100.00 and set a "buy" rating for the company in a report on Friday, November 6th.

Check Out Our Latest Report on GMED

Insider Buying and Selling

In related news, Director James Tobin sold 41,666 shares of the business's stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total value of $3,131,616.56. Following the completion of the sale, the director directly owned 15,000 shares in the company, valued at $1,127,400. The trade was a 73.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ann D. Rhoads sold 5,000 shares of the company's stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the transaction, the director directly owned 35,384 shares in the company, valued at approximately $3,007,640. This represents a 12.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 76,666 shares of company stock worth $5,794,017. 18.38% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Globus Medical

A number of hedge funds and other institutional investors have recently modified their holdings of GMED. Washington Trust Advisors Inc. lifted its position in shares of Globus Medical by 116.8% during the 2nd quarter. Washington Trust Advisors Inc. now owns 45,006 shares of the medical device company's stock valued at $3,556,000 after acquiring an additional 24,250 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Globus Medical during the 2nd quarter worth $1,858,000. Illinois Municipal Retirement Fund grew its holdings in shares of Globus Medical by 24.5% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 73,173 shares of the medical device company's stock worth $5,481,000 after purchasing an additional 14,412 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Globus Medical during the 2nd quarter worth $7,941,000. Finally, Congress Asset Management Co. increased its position in shares of Globus Medical by 6.6% in the third quarter. Congress Asset Management Co. now owns 361,026 shares of the medical device company's stock worth $27,041,000 after purchasing an additional 22,401 shares during the period. Institutional investors and hedge funds own 95.16% of the company's stock.

Globus Medical Price Performance

Shares of Globus Medical stock opened at $70.14 on Wednesday. The business has a fifty day simple moving average of $76.31 and a two-hundred day simple moving average of $82.50. Globus Medical has a 1 year low of $69.49 and a 1 year high of $101.40. The company has a market capitalization of $9.29 billion, a price-to-earnings ratio of 17.23, a P/E/G ratio of 1.09 and a beta of 0.98.

Globus Medical (NYSE:GMED - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, topping analysts' consensus estimates of $1.20 by $0.03. The firm had revenue of $763.72 million during the quarter, compared to analysts' expectations of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The company's revenue for the quarter was down .7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, equities analysts anticipate that Globus Medical will post 4.98 earnings per share for the current fiscal year.

About Globus Medical

(Get Free Report)

Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.

See Also

Analyst Recommendations for Globus Medical (NYSE:GMED)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Globus Medical Right Now?

Before you consider Globus Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.

While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines